Tony Nasser, MD
Cardiovascular Disease · Terre Haute, INNPI 1104803295
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,760 of the $52,093 with a category attached, or 72.5%. Novartis accounts for 62.2% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2019 at $33,944 and has fallen 96.3% since, to $1,259 in 2025. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $213.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$32K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$6K
- Merck$4K
- Medtronic$4K
- Boston Scientific$836
- Abbott$603
- plus $5K from 25 others
What the payments were for
- Consulting fees$3501%
- Speaking & faculty fees$37,76072%
- Travel & lodging$4,4349%
- Food & beverage$9,48318%
- Education$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 94 | $32,405 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $5,811 |
| Merck | 13 | $3,884 |
| Medtronic(2 entities) | 26 | $3,613 |
| Boston Scientific | 34 | $836 |
| Abbott | 6 | $603 |
| Endologix LLC | 1 | $581 |
| Johnson & Johnson | 10 | $578 |
| AstraZeneca | 8 | $578 |
| Abiomed | 4 | $525 |
| Terumo Medical Corporation | 2 | $460 |
| Cardiovascular Systems Inc. | 4 | $397 |
| Bayer | 2 | $242 |
| E.r. Squibb & Sons, L.L.C. | 5 | $240 |
| Boehringer Ingelheim | 2 | $213 |
| W. L. Gore & Associates, Inc. | 1 | $145 |
| Edwards Lifesciences | 1 | $130 |
| Biotronik Inc. | 2 | $124 |
| Asahi Intecc USA, Inc. | 1 | $106 |
| Angiodynamics, Inc. | 1 | $98 |
| Amgen | 1 | $97 |
| Actelion Pharmaceuticals US, Inc. | 1 | $88 |
| Philips North America LLC | 1 | $76 |
| Sanofi-aventis U.S. LLC | 1 | $70 |
| Cardinal Health 200 LLC | 1 | $61 |
| Bard Peripheral Vascular, Inc. | 1 | $49 |
| Cvrx, Inc. | 1 | $30 |
| Amarin Pharma, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$31,317
- VERQUVO$5,700
- LifeVest$5,364
- Endurant$1,020
- ENDURANT IIS$921
- Ovation iX Iliac Stent Graft$581
- MitraClip$431
- Impella$380
- XARELTO$343
- SYMPLICITY G3$324
- AVVIGO Guidance System$170
- FFRangio$159
- Diamondback Peripheral$158
- Diamondback Coronary$146
- EXCLUDER AAA Endoprosthesis$145
- ONYX FRONTIER$144
- Signia$133
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$130
- WATCHMAN FLX$130
- Confirm Rx$130
How this compares
$52,093 in reported general payments places this provider in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 440 | $392,694 |
| EntrestoSacubitril/Valsartan | 262 | $292,312 |
| XareltoRivaroxaban | 172 | $167,395 |
| JardianceEmpagliflozin | 193 | $156,009 |
| Repatha SureclickEvolocumab | 69 | $72,485 |
| FarxigaDapagliflozin Propanediol | 43 | $50,933 |
| BrilintaTicagrelor | 43 | $31,890 |
| Praluent PenAlirocumab | 26 | $20,824 |
| Ranolazine ErRanolazine | 115 | $17,947 |
| VerquvoVericiguat | 14 | $9,214 |
| Atorvastatin Calcium | 919 | $7,135 |
| Ezetimibe | 306 | $6,012 |
| Metoprolol Succinate | 607 | $5,344 |
| ClopidogrelClopidogrel Bisulfate | 616 | $4,864 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 568 | $4,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12 | $392,694440 claims |
| NovartisEntresto | $32,405 | $292,312262 claims |
| Johnson & JohnsonXarelto | $578 | $167,395172 claims |
| Boehringer IngelheimJardiance | $213 | $156,009193 claims |
| AstraZenecaFarxiga, Brilinta | $578 | $82,82386 claims |
| MerckVerquvo | $3,884 | $9,21414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Terre Haute
- Krishna NamburiTerre Haute$73K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.